Cargando…

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane

PURPOSE: Optimal salvage chemotherapy for patients with treated advanced/metastatic gastric cancer (AGC) is unknown. Irinotecan is commonly used in Japan. Ramucirumab, a human IgG-1 monoclonal antibody targeting the extracellular domain of VEGF receptor 2, is the first molecularly targeted agent pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Satake, Hironaga, Sagawa, Tamotsu, Fujikawa, Koshi, Hatachi, Yukimasa, Yasui, Hisateru, Kotaka, Masahito, Kato, Takeshi, Tsuji, Akihito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182742/ https://www.ncbi.nlm.nih.gov/pubmed/30167847 http://dx.doi.org/10.1007/s00280-018-3678-5

Ejemplares similares

First-line chemotherapy with capecitabine/oxaliplatin for advanced gastric cancer: A phase I study
por: Satake, Hironaga, et al.
Publicado: (2017)

Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan
por: Ogata, Misato, et al.
Publicado: (2020)

Oxaliplatin-Induced Hyperammonemic Encephalopathy in a Patient with Metastatic Pancreatic Cancer: A Case Report
por: Ogata, Takatsugu, et al.
Publicado: (2017)

Hyperprogressive Disease in the Irradiation Field after a Single Dose of Nivolumab for Gastric Cancer: A Case Report
por: Ogata, Takatsugu, et al.
Publicado: (2018)

Acute Liver Failure with Diffuse Liver Metastasis from Breast Cancer, Not Detected by Computed Tomography: 2 Case Reports
por: Ogata, Takatsugu, et al.
Publicado: (2018)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study
por: Satake, Hironaga, et al.
Publicado: (2018)

Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study
por: Ogata, Takatsugu, et al.
Publicado: (2018)

Reduction and Escalation in the Dose of Sunitinib Were Adequately Effective against Gastrointestinal Stromal Tumor of the Small Intestine
por: Ogata, Misato, et al.
Publicado: (2019)

Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
por: Satake, Hironaga, et al.
Publicado: (2017)

Evaluation of health-related quality of life via the Computer-Based Health Evaluation System (CHES) for Japanese metastatic breast cancer patients: a single-center pilot study
por: Kikawa, Yuichiro, et al.
Publicado: (2018)

Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection
por: Kotake, Takeshi, et al.
Publicado: (2018)

Safety and effectiveness of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study
por: Ogata, Takatsugu, et al.
Publicado: (2019)

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
por: Ikoma, Tatsuki, et al.
Publicado: (2021)

Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis
por: Wu, Lili, et al.
Publicado: (2021)

Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study
por: Kotani, Daisuke, et al.
Publicado: (2021)

Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
por: Liu, Ying, et al.
Publicado: (2015)

Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)
por: Satake, Hironaga, et al.
Publicado: (2020)

The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies
por: Wang, Tao, et al.
Publicado: (2019)

Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
por: Park, Ji Soo, et al.
Publicado: (2011)

Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial
por: Kuboki, Yasutoshi, et al.
Publicado: (2023)

Hepatectomy Followed by Adjuvant Chemotherapy with 3‐Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases
por: Satake, Hironaga, et al.
Publicado: (2021)

Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer
por: Sasaki, Akinori, et al.
Publicado: (2020)

Hypersensitivity Reactions to Platinum Agents and Taxanes
por: Tsao, Lulu R., et al.
Publicado: (2021)

Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival
por: Matsuo, Koji, et al.
Publicado: (2019)

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
por: Masuishi, Toshiki, et al.
Publicado: (2020)

Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
por: Shoji, Tadahiro, et al.
Publicado: (2012)

Platinum drugs and taxanes: can we overcome resistance?
por: Sazonova, Elena V., et al.
Publicado: (2021)

Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study
por: Nakano, Shintaro, et al.
Publicado: (2020)

Fatal outcome of posterior “reversible” encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen
por: Dedić Plavetić, Natalija, et al.
Publicado: (2014)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Improvement of Body Weight and Nutritional Status in Gastric Cancer Patients Enhances the Benefit of Nivolumab Therapy
por: Ikoma, Tatsuki, et al.
Publicado: (2022)

Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer
por: Kim, S T, et al.
Publicado: (2005)

Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study
por: Taniguchi, Hiroya, et al.
Publicado: (2023)

Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16
por: Yasui, H., et al.
Publicado: (2023)

Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms
por: Imai, Satoshi, et al.
Publicado: (2017)

Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study
por: Arai, Hiroyuki, et al.
Publicado: (2019)

Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
por: Masuishi, Toshiki, et al.
Publicado: (2023)

Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study
por: Ogawa, Kohei, et al.
Publicado: (2012)

Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy
por: Takada, Shinya, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mi9p1j5v0nt88int7j0g5m6hoa